NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
PBYI
Puma Biotechnology, Inc.
PBYI has a slight edge over NVO overall on the model score.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
PBYI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Strong |
PBYI's cash flow and balance sheet are currently strong, and its revenue and profitability are stable.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over PBYI in the historical PE scenario, which offers more potential upside but is not a forecast.
PBYI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.4x | $2.49 | -69% |
| Fair | 12x | $5.71 | -29% |
| Current | 18x | $8.08 | — |
| Expensive | 22x | $10.08 | +25% |
Historical ranges are pointers, not guarantees.
PBYI's PE is in its expensive range at 18x.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
PBYI Forward outlook
There aren't enough analyst estimates for PBYI to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
PBYI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.46 | -39% |
| Q2 2026 | $0.52 | -47% |
| Q1 2026 | $0.48 | -38% |
| Q4 2025 | $0.61 | -1.6% |
| Q3 2025 | $0.75 | +60% |
| Q2 2025 | $0.99 | +450% |
| Q1 2025 | $0.78 | +144% |
| Q4 2024 | $0.62 | +38% |
PBYI's earnings per share have fallen from their peak: $0.46 over the past year, against $0.99 in mid-2025.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over PBYI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over PBYI on profitability, with a higher operating margin.
PBYI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $55.1M | +1.1% |
| Q2 2026 | $56.5M | +7.8% |
| Q1 2026 | $44.8M | -2.6% |
| Q4 2025 | $75.5M | +28% |
| Q3 2025 | $54.5M | -32% |
| Q2 2025 | $52.4M | +11% |
| Q1 2025 | $46M | +5.1% |
| Q4 2024 | $59.1M | -18% |
PBYI's revenue is growing: $55M last quarter, up 1.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.6% | -8 points |
| Q2 2026 | 13% | +0.8 points |
| Q1 2026 | -8.5% | -17 points |
| Q4 2025 | 23% | +0.1 points |
| Q3 2025 | 18% | -9.8 points |
| Q2 2025 | 13% | +17 points |
| Q1 2025 | 8.7% | +14 points |
| Q4 2024 | 23% | +2.1 points |
PBYI's operating margin was 9.6% last quarter, down 8 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
PBYI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $14.6M | +51% |
| Q2 2026 | $1.6M | -88% |
| Q1 2026 | $15.4M | +334% |
| Q4 2025 | $14.5M | -7.3% |
| Q3 2025 | $9.7M | -12% |
| Q1 2025 | $3.6M | -68% |
| Q4 2024 | $15.6M | +50% |
| Q3 2024 | $11M | +4.1% |
PBYI generated $46M in free cash flow over the past year, up 7.5% from the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over PBYI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
PBYI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +520K shares |
| 1 year | +4.3% | +2.2M shares |
| 3 years | +11% | +5.3M shares |
| 5 years | +30% | +12.3M shares |
| Available history | +36% | +14.1M shares |
PBYI has 53M diluted shares, up 4.3% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
PBYI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.1x | Net Cash |
| Q2 2026 | -0.9x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | -0.2x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.1x | Net Cash |
PBYI has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
PBYI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.6 | Neutral |
| Stochastic | 35.7 | Neutral |
PBYI's weekly RSI is 46 (neutral) and its Stochastic is 36 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over PBYI on valuation relative to its sector.
PBYI PE vs Healthcare Sector
| Metric | PBYI | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 32% below |
| PE % | 70 | 29 | 41 pts above |
PBYI is trading at 18x earnings, a 32% discount to the Healthcare sector's median of 26x.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
PBYI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.65 | 16% below |
| 20 week MA | $9.11 | 11% below |
| 50 week MA | $7.65 | 5.6% above |
| 100 week MA | $5.72 | 41% above |
| 200 week MA | $4.69 | 72% above |
PBYI has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
PBYI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.66 | $11.4 | +32% |
| 2021 | $11.4 | $3.46 | -70% |
| 2022 | $3.46 | $4.12 | +19% |
| 2023 | $4.12 | $4.33 | +5.1% |
| 2024 | $4.33 | $3.08 | -29% |
| 2025 | $3.08 | $6.16 | +100% |
| 2026 YTD | $6.16 | $8.08 | +31% |
PBYI has the edge over NVO on returns for 2026, with the stronger performance.